F. Galateau-salle, J. M. Vignaud, L. Burke, A. Gibbs, E. Brambilla et al., Well-differentiated papillary mesothelioma of the pleura: a series of 2 24 cases, Am J Surg Pathol, vol.28, pp.534-540, 2004.

A. Genaidy, T. Tolaymat, R. Sequeira, M. Rinder, and D. Dionysiou, Health effects of 4 exposure to carbon nanofibers: systematic review, critical appraisal, meta analysis and 5 research to practice perspectives, Sci Total Environ, vol.407, pp.3686-3701, 2009.

F. I. Ghani, H. Yamazaki, S. Iwata, T. Okamoto, K. Aoe et al.,

T. Kishimoto, C. W. Yamada, C. Xu, and . Morimoto, Identification of cancer stem 9 cell markers in human malignant mesothelioma cells, Biochem Biophys Res Commun, vol.10, pp.735-742, 2011.

G. J. Gordon, R. V. Jensen, L. L. Hsiao, S. R. Gullans, J. E. Blumenstock et al.,

T. Jaklitsch, D. J. Sugarbaker, and R. Bueno, Using gene expression ratios to 13 predict outcome among patients with mesothelioma, J Natl Cancer Inst, vol.95, pp.598-605, 2003.

G. J. Gordon, L. Dong, B. Y. Yeap, W. G. Richards, J. N. Glickman et al.,

G. Colquitt, B. Maulik, D. J. Van-oss, R. Sugarbaker, and . Bueno, Four-gene 16 expression ratio test for survival in patients undergoing surgery for mesothelioma, Cancer Inst, vol.17, pp.678-686, 2009.

G. J. Gordon, G. N. Rockwell, P. A. Godfrey, R. V. Jensen, J. N. Glickman et al., , p.19

D. J. Richards, R. Sugarbaker, and . Bueno, Validation of genomics-based prognostic 20 tests in malignant pleural mesothelioma, Clin Cancer Res, vol.11, pp.4406-4414, 2005.

E. Goswami, V. Craven, D. L. Dahlstrom, D. Alexander, and F. Mowat, Domestic 23 asbestos exposure: a review of epidemiologic and exposure data, Int J Environ Res Public 24 Health, vol.10, pp.5629-5670, 2013.

Y. Goto, K. Shinjo, Y. Kondo, L. Shen, M. Toyota et al., , p.26

H. Murakami, T. Osada, N. Taniguchi, M. Usami, Y. Kondo et al., , p.27

K. Matsuo, T. Hida, N. Fujimoto, T. Kishimoto, J. P. Issa et al., 28 Epigenetic profiles distinguish malignant pleural mesothelioma from lung 29 adenocarcinoma, Cancer Res, vol.69, pp.9073-9082, 2009.

H. Greim, M. J. Utell, L. D. Maxim, and R. Niebo, Perspectives on refractory ceramic 31 fiber (RCF) carcinogenicity: comparisons with other fibers, Inhal Toxicol, vol.26, 2014.

Y. Grosse, D. Loomis, K. Z. Guyton, B. Lauby-secretan, F. E. Ghissassi et al., , p.34

N. Benbrahim-tallaa, C. Guha, H. Scoccianti, K. Mattock, and . Straif, , 2014.

, Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon 36 nanotubes, Lancet Oncol, vol.15, pp.1427-1428

G. Guo, J. Chmielecki, C. Goparaju, A. Heguy, I. Dolgalev et al., , p.38

H. I. Meyerson and . Pass, Whole exome sequencing reveals frequent genetic 39 alterations in BAP1, NF2, CDKN2A and CUL1 in malignant pleural mesothelioma, 2015.

, Cancer Res, vol.75, pp.264-269

J. M. Hillegass, J. M. Miller, M. B. Macpherson, C. M. Westbom, M. Sayan et al.,

L. Macura, T. N. Perkins, S. L. Beuschel, V. Alexeeva, H. I. Pass et al.,

A. Mossman and . Shukla, Asbestos and erionite prime and activate the NLRP3 44 inflammasome that stimulates autocrine cytokine release in human mesothelial cells, vol.10, p.39, 2013.

G. Hillerdal, Mesothelioma: cases associated with non-occupational and low dose 1 exposures, Occup Environ Med, vol.56, pp.505-513, 1999.

C. D. Hoang, J. Cunha, M. G. Kratzke, C. E. Casmey, S. P. Frizelle et al.,

A. Kratzke, Gene expression profiling identifies matriptase overexpression in 4 malignant mesothelioma, Chest, vol.125, pp.1843-1852, 2004.

A. J. Holloway, D. S. Diyagama, K. Opeskin, J. Creaney, B. W. Robinson et al.,

. Bowtell, A molecular diagnostic test for distinguishing lung adenocarcinoma from 7 malignant mesothelioma using cells collected from pleural effusions, Clin Cancer Res, vol.8, pp.5129-5135, 2006.

A. N. Husain, T. Colby, N. Ordonez, T. Krausz, R. Attanoos et al.,

P. T. Butnor, L. R. Cagle, A. Chirieac, S. Churg, A. Dacic et al.,

A. Gibbs, S. Gown, L. Hammar, A. M. Litzky, A. Marchevsky et al.,

D. Travis and M. Wick, Guidelines for Pathologic Diagnosis of Malignant 13 Mesothelioma: 2012 Update of the Consensus Statement from the International 14, 2013.

, Mesothelioma Interest Group. Arch Pathol Lab Med, vol.137, pp.647-667

H. C. Hwang, B. S. Sheffield, S. Rodriguez, K. Thompson, C. H. Tse et al.,

. Churg, Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the 18 Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens, Am J Surg 19 Pathol, vol.40, pp.120-126, 2015.

, IARC Monograph on the valuation of 21 carcinogenic risks to humans, vol.81, 2002.

, C IARC 23 Monographs on the Evaluation of Carcinogenic Risks to Humans, IARC. 2012. Arsenic, metals, fibres, and dusts. A review of human carcinogens, vol.100

B. Jasani and A. Gibbs, Mesothelioma not associated with asbestos exposure, Arch Pathol, vol.25, pp.262-267, 2012.

M. C. Jaurand, Health effects of carbon nanotubes and some comparisons with natural 27 mineral nanotubes, Natural mineral nanotubes. Properties and applications, p.29, 2015.

M. C. Jaurand, In press. Safety of tubular clay minerals: an overview, Nanosized Tubular Clay 31 Minerals

M. C. Jaurand and D. Jean, Biomolecular Pathways and Malignant Pleural Mesothelioma, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02479956

, Malignant Pleural Mesothelioma: Present Status and Future Directions

C. Mineo and U. A. Sharjah,

D. Jean, J. Daubriac, F. L. Pimpec-barthes, F. Galateau-salle, and M. C. Jaurand, 36 Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch 37 Pathol Lab Med, vol.136, pp.277-293, 2012.

D. Jean, E. Thomas, A. Renier, A. De-reynies, C. Lecomte et al., , p.39

J. Giovannini, M. H. Zucman-rossi, M. C. Stern, and . Jaurand, Syntenic 40 relationships between genomic profiles of fiber-induced murine and human malignant 41 mesothelioma, Am J Pathol, vol.176, pp.881-894, 2011.

T. Kameda, K. Takahashi, R. Kim, Y. Jiang, M. Movahed et al., 43 Asbestos: use, bans and disease burden in Europe, Bull World Health Organ, vol.92, pp.790-797, 2014.

M. S. Kanarek, Mesothelioma from chrysotile asbestos: update, Ann Epidemiol, vol.21, pp.688-734, 2011.

H. C. Kang, H. K. Kim, S. Lee, P. Mendez, J. W. Kim et al.,

K. Fang, D. M. Jones, I. J. Jablons, and . Kim, Whole exome and targeted deep 2 sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in 3 malignant pleural mesotheliomas, Oncotarget, 2016.

S. C. Kao, M. Fulham, K. Wong, W. Cooper, H. Brahmbhatt et al.,

Y. Sagong, F. Huynh, N. Leslie, S. Pavlakis, M. Clarke et al.,

. Zandwijk, A Significant Metabolic and Radiological Response after a Novel 7 Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma, Am 8 J Respir Crit Care Med, vol.191, pp.1467-1469, 2015.

J. Kayat, V. Gajbhiye, R. K. Tekade, and N. K. Jain, Pulmonary toxicity of carbon 10 nanotubes: a systematic report, Nanomedicine, vol.7, pp.40-49, 2011.

M. B. Kirschner, Y. Y. Cheng, N. J. Armstrong, R. C. Lin, S. C. Kao et al., , p.12

N. Mccaughan, G. Van-zandwijk, and . Reid, MiR-score: a novel 6-microRNA 13 signature that predicts survival outcomes in patients with malignant pleural mesothelioma, 2015.

, Mol Oncol, vol.9, pp.715-726

G. Klorin, E. Rozenblum, O. Glebov, R. L. Walker, Y. Park et al., , p.16

A. V. Kaye and . Roschke, Integrated high-resolution array CGH and SKY analysis 17 of homozygous deletions and other genomic alterations present in malignant 18 mesothelioma cell lines, Cancer Genet, vol.206, pp.191-205, 2013.

U. P. Kodavanti, D. Andrews, M. C. Schladweiler, S. H. Gavett, D. E. Dodd et al., Early and delayed effects of naturally occurring asbestos on serum biomarkers of 22 inflammation and metabolism, J Toxicol Environ Health A, vol.21, pp.1024-1039, 2014.

N. Kurumatani and S. Kumagai, Mapping the risk of mesothelioma due to neighborhood 25 asbestos exposure, Am J Respir Crit Care Med, vol.178, pp.624-629, 2008.

A. Lacourt, C. Gramond, S. Audignon, S. Ducamp, J. Fevotte et al., , p.28

P. Imbernon and . Brochard, Pleural mesothelioma and occupational coexposure to 29 asbestos, mineral wool, and silica, Am J Respir Crit Care Med, vol.187, pp.977-982, 2013.

A. Lacourt, M. Rinaldo, C. Gramond, S. Ducamp, A. Gilg-soit-ilg et al., Co-exposure to refractory ceramic fibres and asbestos and risk of 33 pleural mesothelioma, Eur Respir J, vol.44, pp.725-733, 2014.

S. M. Langevin, M. H. O'sullivan, J. L. Valerio, M. Pawlita, K. M. Applebaum et al.,

K. T. Mcclean and . Kelsey, Occupational asbestos exposure is associated with 36 pharyngeal squamous cell carcinoma in men from the greater Boston area, Occup Environ 37 Med, vol.70, pp.858-863, 2013.

B. Lecouvet, Some further industrial, environmental and biomedical applications of 39 halloysite nanotubes, Natural mineral nanotubes. Properties and applications, 2015.

B. Li, S. P. Tang, and K. Z. Wang, Esophagus cancer and occupational exposure to 43 asbestos: results from a meta-analysis of epidemiology studies, 2015.

C. B. Lim, C. M. Prele, H. M. Cheah, Y. Y. Cheng, S. Klebe et al., , p.46

P. J. Thompson and S. E. Mutsaers, Mutational analysis of hedgehog signaling 47 pathway genes in human malignant mesothelioma, PLoS ONE, vol.8, 2013.

M. Lippmann, Toxicological and epidemiological studies on effects of airborne fibers: 3 coherence and public [corrected] health implications, Crit Rev Toxicol, vol.44, pp.643-695, 2014.

M. Lo-iacono, V. Monica, L. Righi, F. Grosso, R. Libener et al.,

M. Musmeci, M. Volante, G. V. Papotti, and . Scagliotti, Targeted next-generation 7 sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a 8 retrospective study, J Thorac Oncol, vol.10, pp.492-499, 2015.

J. E. Lockey, G. K. Lemasters, L. Levin, C. Rice, J. Yiin et al., A 10 longitudinal study of chest radiographic changes of workers in the refractory ceramic 11 fiber industry, Chest, vol.121, pp.2044-2051, 2002.

J. Lockey, G. Lemsters, C. Rice, K. Hansen, L. Levin et al., 13 Refractory ceramic fiber exposure and pleural plaques, Am J Respir Crit Care Med, vol.14, pp.1405-1410, 1996.

F. Lopez-rios, S. Chuai, R. Flores, S. Shimizu, T. Ohno et al.,

M. F. Krug, V. Zakowski, A. B. Rusch, M. Olshen, and . Ladanyi, Global gene 17 expression profiling of pleural mesotheliomas: overexpression of aurora kinases and 18 P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based 19 prognostic prediction, Cancer Res, vol.66, pp.2970-2979, 2006.

S. Maisanaba, S. Pichardo, M. Puerto, D. Gutierrez-praena, A. M. Camean et al., 21 Toxicological evaluation of clay minerals and derived nanocomposites: a review, Environ 22 Res, vol.138, pp.233-254, 2015.

S. Matsumoto, K. Nabeshima, M. Hamasaki, T. Shibuta, and T. Umemura, Upregulation 24 of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma 25 with sarcomatoid component, Med Oncol, vol.31, p.303, 2014.

O. Melaiu, E. Bracci, A. Cristaudo, A. Bonotti, R. Foddis et al., Comparative Genomic Hybridization Studies on Mesothelioma Show a Parallel 28 Fate of 1p21-1p22 and 9p21 Bands and a Chromosomally Stable Sub-Group, American 29 Journal of Medical and Biological Research, vol.27, pp.149-158, 2013.

O. Melaiu, A. Cristaudo, E. Melissari, M. D. Russo, A. Bonotti et al., , p.31

S. Gemignani, S. Pellegrini, and . Landi, A review of transcriptome studies 32 combined with data mining reveals novel potential markers of malignant pleural 33 mesothelioma, Mutat Res, vol.750, pp.132-140, 2012.

O. Melaiu, E. Melissari, L. Mutti, E. Bracci, C. Santi et al., , p.35

A. Bonotti, M. Cipollini, S. I. Garritano, R. Foddis, M. Lucchi et al., , p.36

S. Gemignani and . Landi, Expression status of candidate genes in mesothelioma 37 tissues and cell lines, Mutat Res, vol.771, pp.6-12, 2015.

G. Menvielle, A. Fayosse, L. Radoi, F. Guida, M. Sanchez et al.,

J. Cenee, P. Fevotte, I. Delafosse, D. Stucker, and . Luce, The joint effect of asbestos 40 exposure, tobacco smoking and alcohol drinking on laryngeal cancer risk: evidence from 41 the French population-based case-control study, ICARE, Occup Environ Med, vol.73, 2016.

R. Mezzapelle, U. Miglio, O. Rena, A. Paganotti, S. Allegrini et al., , p.44

G. Frattini, O. Monga, R. Alabiso, and . Boldorini, Mutation analysis of the EGFR 45 gene and downstream signalling pathway in histologic samples of malignant pleural 46 mesothelioma, Br J Cancer, vol.108, pp.1743-1749, 2013.

A. Miyanaga, M. Masuda, K. Tsuta, K. Kawasaki, Y. Nakamura et al.,

T. Gemma and . Yamada, Hippo pathway gene mutations in malignant 2 mesothelioma: revealed by RNA and targeted exon sequencing, J Thorac Oncol, vol.10, pp.844-847, 2015.

H. Murakami, T. Mizuno, T. Taniguchi, M. Fujii, F. Ishiguro et al., , p.5

T. Hida, Y. Kondo, S. Toyokuni, H. Osada, and Y. Sekido, LATS2 Is a Tumor 6 Suppressor Gene of Malignant Mesothelioma, Cancer Res, vol.71, pp.873-883, 2011.

R. Murali, T. Wiesner, and R. A. Scolyer, Tumours associated with BAP1 mutations, vol.9, pp.116-126, 2013.

A. W. Musk, N. Olsen, H. Alfonso, A. Reid, R. Mina et al.,

K. B. Threlfall, N. H. Shilkin, and . De-klerk, Predicting survival in malignant 12 mesothelioma, Eur Respir J, vol.38, pp.1420-1424, 2011.

M. Nasu, M. Emi, S. Pastorino, M. Tanji, A. Powers et al.,

S. Gazdar, M. Kanodia, E. Tiirikainen, G. Flores, M. J. Gaudino et al.,

M. Yang and . Carbone, High Incidence of Somatic BAP1 alterations in sporadic 16 malignant mesothelioma, J Thorac Oncol, vol.10, pp.565-576, 2015.

. Niosh, Asbestos fibers and other elongate mineral particles: State of the science and 19 roadmap for research, Current Intelligence Bulletin, vol.62, pp.1-153, 2011.

N. S. Offermans, R. Vermeulen, A. Burdorf, R. A. Goldbohm, T. Kauppinen et al., Occupational asbestos exposure and risk of pleural 22 mesothelioma, lung cancer, and laryngeal cancer in the prospective Netherlands cohort 23 study, J Occup Environ Med, vol.56, pp.6-19, 2014.

N. S. Offermans, R. Vermeulen, A. Burdorf, R. A. Goldbohm, A. P. Keszei et al., , p.25

H. Kauppinen, P. A. Kromhout, . Van-den, and . Brandt, Occupational asbestos 26 exposure and risk of esophageal, gastric and colorectal cancer in the prospective 27 Netherlands Cohort Study, Int J Cancer, vol.135, pp.1970-1977, 2014.

M. A. Ortega-guerrero, G. Carrasco-nunez, H. Barragan-campos, and M. R. Ortega, 29 High incidence of lung cancer and malignant mesothelioma linked to erionite fibre 30 exposure in a rural community in Central Mexico, Occup Environ Med, vol.72, pp.216-218, 2015.

J. C. Pairon, P. Andujar, M. Rinaldo, J. Ameille, P. Brochard et al., , p.33

A. Ferretti, F. Gislard, A. Laurent, P. Luc, C. Wild et al., Asbestos exposure, 34 pleural plaques, and the risk of death from lung cancer, Am J Respir Crit Care Med, vol.35, pp.1413-1420, 2014.

J. C. Pairon, F. Laurent, M. Rinaldo, B. Clin, P. Andujar et al., , p.37

G. Chammings, F. Ferretti, A. Galateau-salle, M. Gislard, A. Letourneux et al.,

C. Schorle and . Paris, Pleural plaques and the risk of pleural mesothelioma, Cancer Inst, vol.39, pp.293-301, 2013.

I. Panagopoulos, J. Thorsen, L. Gorunova, F. Micci, L. Haugom et al., RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma, vol.41, 2013.

, Genes Chromosomes Cancer, vol.52, pp.733-740

V. Panou, M. Vyberg, U. M. Weinreich, C. Meristoudis, U. G. Falkmer et al., 45 The established and future biomarkers of malignant pleural mesothelioma, Cancer Treat, vol.46, pp.486-495, 2015.

E. A. Pasdar, M. Smits, M. Stapelberg, M. Bajzikova, M. Stantic et al., , p.1

J. Kovarova, K. Sachaphibulkij, A. Bezawork-geleta, M. Sobol, A. Filimonenko et al.,

R. Tomasetti, P. Zobalova, L. F. Hozak, J. Dong, and . Neuzil, Characterisation of 3 mesothelioma-initiating cells and their susceptibility to anti-cancer agents, PLoS ONE, vol.4, 2015.

H. I. Pass, C. Goparaju, S. Ivanov, J. Donington, M. Carbone et al., , p.6

S. Rosenwald, H. Dan, S. Benjamin, and R. Aharonov, hsa-miR-29c* Is Linked to 7 the Prognosis of Malignant Pleural Mesothelioma, Cancer Res, vol.70, pp.1916-1924, 2010.

H. I. Pass, Z. Liu, A. Wali, R. Bueno, S. Land et al., Gene expression profiles predict survival and progression of pleural 10 mesothelioma, Clin Cancer Res, vol.10, pp.849-859, 2004.

G. J. Peters, A. Avan, M. G. Ruiz, V. Orsini, A. Avan et al., , p.12, 2014.

, Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic 13 and lung cancer, Anticancer Res, vol.34, pp.435-442

A. M. Petrilli and C. Fernandez-valle, Role of Merlin/NF2 inactivation in tumor biology, 15 Oncogene, vol.35, pp.537-548, 2015.

J. Pintos, M. E. Parent, B. W. Case, M. C. Rousseau, and J. Siemiatycki, Risk of 17 mesothelioma and occupational exposure to asbestos and man-made vitreous fibers: 18 evidence from two case-control studies in Montreal, Canada, J Occup Environ Med, vol.19, pp.1177-1184, 2009.

S. Pohl, R. Scott, F. Arfuso, V. Perumal, and A. Dharmarajan, Secreted frizzled-related 21 protein 4 and its implications in cancer and apoptosis, Tumour Biol, vol.36, pp.143-152, 2015.

E. Pukkala, J. I. Martinsen, E. Weiderpass, K. Kjaerheim, E. Lynge et al., Cancer incidence among firefighters: 45 years of follow-up in 25 five Nordic countries, Occup Environ Med, vol.71, pp.398-404, 2014.

C. Rake, C. Gilham, J. Hatch, A. Darnton, J. Hodgson et al., Occupational, 28 domestic and environmental mesothelioma risks in the British population: a case-control 29 study, Br J Cancer, vol.100, pp.1175-1183, 2009.

V. Rapisarda, C. Ledda, V. Ricceri, F. Arena, A. Musumeci et al., , p.31

M. Santarelli and . Ferrante, Detection of pleural plaques in workers exposed to 32 inhalation of natural fluoro-edenite fibres, Oncol Lett, vol.9, pp.2046-2052, 2015.

A. Reid, P. Franklin, N. Olsen, J. Sleith, L. Samuel et al.,

. Musk, All-cause mortality and cancer incidence among adults exposed to blue 36 asbestos during childhood, Am J Ind Med, vol.56, pp.133-145, 2013.

G. Reid, MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to 38 therapeutic targets, J Thorac Dis, vol.7, pp.1031-1040, 2015.

B. W. Robinson, A. W. Musk, and R. A. Lake, Malignant mesothelioma, Lancet, vol.366, pp.397-438, 2005.

K. Rodelsperger, K. H. Jockel, H. Pohlabeln, W. Romer, and H. J. Woitowitz, Asbestos 43 and man-made vitreous fibers as risk factors for diffuse malignant mesothelioma: results 44 from a German hospital-based case-control study, Am J Ind Med, vol.39, pp.262-275, 2001.

P. Rolland, C. Gramond, A. Lacourt, P. Astoul, S. Chamming's et al.,

A. G. Galateau-salle, E. Ilg, N. L. Imbernon, J. C. Stang, M. Pairon et al.,

. Brochard, Occupations and industries in France at high risk for pleural 1 mesothelioma: A population-based case-control study (1998-2002), Am J Ind Med, vol.2, pp.1207-1219, 2010.

A. Rusch, G. Ziltener, K. Nackaerts, W. Weder, R. A. Stahel et al., 4 Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant 5 pleural mesothelioma cases, Lung Cancer, vol.87, pp.77-79, 2015.

A. Scherpereel, P. Astoul, P. Baas, T. Berghmans, H. Clayson et al.,

C. Galateau-salle, G. Hennequin, C. L. Hillerdal, L. Pechoux, J. C. Mutti et al.,

P. Stahel, J. Van-houtte, D. Van-meerbeeck, W. Waller, and . Weder, Guidelines of 9 the European Respiratory Society and the European Society of Thoracic Surgeons for the 10 management of malignant pleural mesothelioma, Eur Respir J, vol.35, pp.479-495, 2010.

V. Schildgen, O. Pabst, R. L. Tillmann, J. Lusebrink, O. Schildgen et al., Low frequency of EGFR mutations in pleural mesothelioma 13 patients, Appl Immunohistochem Mol Morphol, vol.23, pp.118-125, 2015.

P. Sebastien, A. Fondimare, J. Bignon, G. Monchaux, J. Desbordes et al., , p.16, 1975.

, Topographic distribution of asbestos fibres in human lung in relation to occupational and 17 non-occupational exposure, Inhaled Part, vol.4, pp.435-446

Y. Sekido, Genomic abnormalities and signal transduction dysregulation in malignant 19 mesothelioma cells, Cancer Sci, vol.101, pp.1-6, 2010.

Y. Sekido, Molecular pathogenesis of malignant mesothelioma, Carcinogenesis, vol.34, pp.1413-1434, 2013.

I. J. Selikoff, J. Churg, and E. C. Hammond, Asbestos exposure and neoplasia, Jama, vol.23, pp.22-26, 1964.

T. Shukuya, M. Serizawa, M. Watanabe, H. Akamatsu, M. Abe et al., , p.25

H. Taira, T. Kenmotsu, H. Naito, T. Murakami, M. Takahashi et al.,

N. Nakajima, Y. Yamamoto, and . Koh, Identification of actionable mutations in 27 malignant pleural mesothelioma, Lung Cancer, vol.86, 2014.

A. A. Shvedova, E. R. Kisin, D. Porter, P. Schulte, V. E. Kagan et al., Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: 31 Two faces of Janus?, Pharmacol Ther, vol.121, pp.192-204, 2009.

A. A. Shvedova, N. Yanamala, E. R. Kisin, T. O. Khailullin, M. E. Birch et al., , p.33

. Fatkhutdinova, Integrated Analysis of Dysregulated ncRNA and mRNA Expression 34 Profiles in Humans Exposed to Carbon Nanotubes, PLoS One, vol.11, 2016.

F. W. Simson, Pulmonary asbestosis in South Africa, Br Med J, vol.1, issue.3516, pp.885-887, 1928.

R. Spirtas, E. F. Heineman, L. Bernstein, G. W. Beebe, R. J. Keehn et al., Malignant mesothelioma: attributable risk of asbestos exposure, Environ Med, vol.40, pp.804-811, 1994.

L. Stayner, L. S. Welch, and R. Lemen, The worldwide pandemic of asbestos-related 42 diseases, Annu Rev Public Health, vol.34, pp.205-216, 2013.

M. B. Suraokar, M. I. Nunez, L. Diao, C. W. Chow, D. Kim et al., , p.45

C. Raso, D. Moran, R. Rice, J. J. Mehran, H. I. Lee et al.,

A. James, K. Corvalan, A. Coombes, . Tsao, and I. I. Wistuba, Expression profiling 47 stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway 1 and microtubule network with therapeutic implications, Ann Oncol, vol.25, pp.1184-1192, 2014.

A. Tallet, J. C. Nault, A. Renier, I. Hysi, F. Galateau-salle et al., , p.4

P. Andujar, F. L. Pimpec-barthes, J. Zucman-rossi, M. C. Jaurand, and D. Jean, 5 Overexpression and promoter mutation of the TERT gene in malignant pleural 6 mesothelioma, Oncogene, vol.33, pp.3748-3452, 2014.

J. Tarres, C. Alberti, X. Martinez-artes, R. Abos-herrandiz, M. Rosell-murphy et al., , vol.8

I. Krier, G. Cantarell, M. Gallego, J. Canela-soler, and R. Orriols, Pleural 9 mesothelioma in relation to meteorological conditions and residential distance from an 10 industrial source of asbestos, Occup Environ Med, vol.70, pp.588-590, 2013.

J. R. Testa, M. Cheung, J. Pei, J. E. Below, Y. Tan et al.,

S. Pass, M. Trusa, M. Hesdorffer, A. Nasu, Z. Powers et al., , p.14

H. Gaudino, M. Yang, and . Carbone, Germline BAP1 mutations predispose to 15 malignant mesothelioma, Nat Genet, vol.43, pp.1022-1025, 2011.

S. Thies, M. Friess, L. Frischknecht, D. Korol, E. Felley-bosco et al., , p.17

I. Opitz and A. Soltermann, Expression of the Stem Cell Factor Nestin in 18 Malignant Pleural Mesothelioma Is Associated with Poor Prognosis, PLoS ONE, vol.19, 2015.

C. Thurneysen, I. Opitz, S. Kurtz, W. Weder, R. A. Stahel et al., 21 Functional inactivation of NF2/merlin in human mesothelioma, Lung Cancer, vol.64, pp.140-147, 2009.

D. Toumpanakis and S. E. Theocharis, DNA repair systems in malignant mesothelioma, 2011.

, Cancer Lett, vol.312, pp.143-149

C. L. Tran, R. Trantra, K. Donaldson, V. Stone, S. M. Hankin et al.,

. Jones, A hypothetical model for predicting the toxicity of high aspect ratio 27 nanoparticles (HARN), J Nanopart Res, vol.13, pp.6683-6698, 2011.

P. A. Tran, L. Zhang, and T. J. Webster, Carbon nanofibers and carbon nanotubes in 29 regenerative medicine, Adv Drug Deliv Rev, vol.61, 2009.

T. Ueno, S. Toyooka, T. Fukazawa, T. Kubo, J. Soh et al.,

K. Maki, M. Shien, M. Furukawa, H. Sakaguchi, K. Yamamoto et al.,

. Miyoshi, Preclinical evaluation of microRNA-34b/c delivery for malignant pleural 34 mesothelioma, Acta Med Okayama, vol.68, pp.23-26, 2014.

V. K. Upadhyayula, S. Deng, M. C. Mitchell, and G. B. Smith, Application of carbon 36 nanotube technology for removal of contaminants in drinking water: a review, Sci Total 37 Environ, vol.408, pp.1-13, 2009.

V. Vahedi and P. Pasbakhsh, Applications of natural mineral nanotubes in nanocomposites, 2015.

, Natural mineral nanotubes. Properties and applications, p.41

S. Van-der-bij, H. Koffijberg, V. Lenters, L. Portengen, K. G. Moons et al., , p.43

. Vermeulen, Lung cancer risk at low cumulative asbestos exposure: meta-regression 44 of the exposure-response relationship, Cancer Causes Control, vol.24, 2013.

F. Vandermeers, S. Sriramareddy, C. Costa, R. Hubaux, J. P. Cosse et al., The role of epigenetics in malignant pleural mesothelioma, Lung Cancer, vol.1, pp.311-313, 2013.

J. C. Wagner, C. A. Sleggs, and P. Marchand, Diffuse pleural mesothelioma and asbestos 4 exposure in the North Western Cape Province, Br J Ind Med, vol.17, pp.260-271, 1960.

S. Xio, D. Li, J. Vijg, D. J. Sugarbaker, J. M. Corson et al., Codeletion of 6 p15 and p16 in primary malignant mesothelioma, Oncogene, vol.11, pp.511-515, 1995.

J. Xu, Y. Kadariya, M. Cheung, J. Pei, J. Talarchek et al.,

S. Cai, H. Litwin, J. Peng, F. J. Karar, J. R. Rauscher et al., Germline mutation 9 of Bap1 accelerates development of asbestos-induced malignant mesothelioma, Cancer 10 Res, vol.74, pp.4388-4397, 2014.

Y. Yoshikawa, A. Sato, T. Tsujimura, M. Emi, T. Morinaga et al.,

N. Murakami, S. Kondo, Y. Matsumoto, F. Okumura, S. Tanaka et al., Frequent inactivation of the BAP1 gene in epithelioid-14 type malignant mesothelioma, Cancer Sci, vol.103, pp.868-874, 2012.

G. Zalcman, J. Mazieres, J. Margery, L. Greillier, C. Audigier-valette et al.,

R. Molinier, I. Corre, V. Monnet, F. Gounant, H. Riviere et al., , p.18

B. Milleron, Q. Tran, M. P. Lebitasy, F. Morin, C. Creveuil et al., Bevacizumab for newly diagnosed 20 pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): 21 a randomised, controlled, open-label, pp.1238-1244, 2015.

M. G. Zauderer, M. Bott, R. Mcmillan, C. S. Sima, V. Rusch et al., Clinical characteristics of patients with malignant pleural mesothelioma harboring 25 somatic BAP1 mutations, J Thorac Oncol, vol.24, pp.1430-1433, 2013.